CY1109425T1 - Φαρμακευτικες συνθεσεις για τη χορηγηση με ελεγχομενη αποδεσμευση βιολογικα δραστικων ενωσεων - Google Patents
Φαρμακευτικες συνθεσεις για τη χορηγηση με ελεγχομενη αποδεσμευση βιολογικα δραστικων ενωσεωνInfo
- Publication number
- CY1109425T1 CY1109425T1 CY20091100618T CY091100618T CY1109425T1 CY 1109425 T1 CY1109425 T1 CY 1109425T1 CY 20091100618 T CY20091100618 T CY 20091100618T CY 091100618 T CY091100618 T CY 091100618T CY 1109425 T1 CY1109425 T1 CY 1109425T1
- Authority
- CY
- Cyprus
- Prior art keywords
- biologically active
- active compounds
- methods
- provides
- controlled
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Abstract
Η παρούσα εφεύρεση παρέχει συνθέσεις και μεθόδους για τη χορήγηση με ελεγχόμενη αποδέσμευση μιας ή περισσότερων βιολογικά δραστικών ενώσεων σε κάποιο ασθενή. Συγκεκριμένα, η εφεύρεση παρέχει μια φαρμακευτική σύνθεση για τη χορήγηση με ελεγχόμενη αποδέσμευση βιολογικά δραστικών ενώσεων σε κάποιο ασθενή, η οποία περιέχει: α) ένα σύμπλοκο μιας βιολογικά δραστικής ένωσης, η οποία έχει τουλάχιστον μία βασική λειτουργική ομάδα και ενός πολυανιόντος που προέρχεται από εξαϋδροξυκυκλοεξάνιο, το οποίο έχει τουλάχιστον δύο αρνητικά φορτισμένες λειτουργικές ομάδες, και β) ένα φαρμακευτικά αποδεκτό φορέα που περιέχει ένα βιοδιασπώμενο, αδιάλυτο στο νερό πολυμερές. Με τη συμπλοκοποίηση μιας βιολογικά δραστικής ένωσης με ένα πολυανιόν, το συμπαγές, σταθερό σύμπλοκο μπορεί να ενσωματωθεί σε ένα σύστημα δοσολογίας μακράς δράσης, το οποίο έχει μια περισσότερο επιθυμητή καμπύλη αποδέσμευσης φαρμάκου σε βάθος χρόνου σε σχέση με αυτή της στάθμης της τεχνικής. Η εφεύρεση παρέχει επίσης τις μεθόδους για την παραγωγή αυτών των συνθέσεων και τις μεθόδους χρήσης τους.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60090704P | 2004-08-12 | 2004-08-12 | |
EP05807464A EP1786400B1 (en) | 2004-08-12 | 2005-08-11 | Pharmaceutical compositions for controlled release delivery of biologically active compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1109425T1 true CY1109425T1 (el) | 2014-08-13 |
Family
ID=35839986
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20091100618T CY1109425T1 (el) | 2004-08-12 | 2009-06-11 | Φαρμακευτικες συνθεσεις για τη χορηγηση με ελεγχομενη αποδεσμευση βιολογικα δραστικων ενωσεων |
Country Status (21)
Country | Link |
---|---|
US (1) | US7964219B2 (el) |
EP (1) | EP1786400B1 (el) |
JP (1) | JP5053846B2 (el) |
KR (1) | KR101231856B1 (el) |
CN (1) | CN101035512B (el) |
AT (1) | ATE424848T1 (el) |
AU (1) | AU2005271242B9 (el) |
BR (1) | BRPI0514297A (el) |
CA (1) | CA2576689C (el) |
CY (1) | CY1109425T1 (el) |
DE (1) | DE602005013244D1 (el) |
DK (1) | DK1786400T3 (el) |
ES (1) | ES2323141T3 (el) |
HK (1) | HK1108638A1 (el) |
MX (1) | MX2007001760A (el) |
NZ (1) | NZ553149A (el) |
PL (1) | PL1786400T3 (el) |
PT (1) | PT1786400E (el) |
RU (1) | RU2390355C2 (el) |
SI (1) | SI1786400T1 (el) |
WO (1) | WO2006017852A2 (el) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1786400B1 (en) * | 2004-08-12 | 2009-03-11 | Quest Pharmaceutical Services | Pharmaceutical compositions for controlled release delivery of biologically active compounds |
ITRM20050344A1 (it) * | 2005-06-30 | 2007-01-01 | Luca Maria De | Sali o complessi di sostanze metil-donatrici con acido fitico o suoi derivati e relativo metodo di sintesi. |
EP1971362B1 (en) | 2005-08-19 | 2014-12-03 | Amylin Pharmaceuticals, LLC | Exendin for treating diabetes and reducing body weight |
PT1968549E (pt) * | 2005-12-22 | 2014-08-29 | Novartis Ag | Formulação de libertação controlada compreendendo octreotida e dois ou mais polímeros de polilactídeo-co-glicolídeo |
EP1984009B1 (en) * | 2006-01-18 | 2012-10-24 | Qps, Llc | Pharmaceutical compositions with enhanced stability |
PT2034951E (pt) | 2006-06-22 | 2013-04-18 | Biocompatibles Uk Ltd | Produto farmacêutico reidratável |
EP1917971A1 (en) | 2006-10-27 | 2008-05-07 | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) | Substained release formulations comprising very low molecular weight polymers |
KR100805208B1 (ko) * | 2007-03-27 | 2008-02-21 | 주식회사 펩트론 | 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법 |
MX2009011123A (es) * | 2007-04-23 | 2009-11-02 | Intarcia Therapeutics Inc | Formulaciones de suspensiones de peptidos insulinotropicos y sus usos. |
CA2698824A1 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of peptide yy, alone or in combination with glucagon-like peptide, for use in medicine |
US8551072B2 (en) | 2007-12-12 | 2013-10-08 | Boston Scientific Scimed, Inc. | Methods, devices and compositions for controlled drug delivery to injured myocardium |
BRPI0905707B1 (pt) * | 2008-01-18 | 2024-02-27 | Dow Global Technologies Inc | Método para aumentar a solubilidade aquosa de um composto ativo e composição compreendendo um composto ativo |
WO2009143285A2 (en) | 2008-05-21 | 2009-11-26 | Amylin Pharmaceuticals, Inc. | Exendins to lower cholestrol and triglycerides |
WO2009148583A2 (en) * | 2008-06-03 | 2009-12-10 | Qlt Usa, Inc. | Method for improvement of octreotide bioavailability |
EP2213307A1 (en) * | 2009-02-03 | 2010-08-04 | Novartis AG | Injectable depot formulations |
ES2600797T3 (es) * | 2008-08-12 | 2017-02-10 | Novartis Ag | Composiciones farmacéuticas |
KR101258336B1 (ko) | 2008-10-02 | 2013-04-25 | 밀란 인크. | 다층 접착제 라미네이트를 제조하는 방법 |
US20100086597A1 (en) * | 2008-10-06 | 2010-04-08 | Oakwood Laboratories LLC | Microspheres for the sustained release of octreotide with a low initial burst |
WO2010123563A2 (en) * | 2009-04-23 | 2010-10-28 | Sustained Nano Systems Llc | Controlled release dispensing device |
US9498440B2 (en) | 2009-05-22 | 2016-11-22 | Inventia Healthcare Private Limited | Extended release pharmaceutical compositions |
US20120108514A1 (en) | 2009-07-09 | 2012-05-03 | University Of Iowa Research Foundation | Long acting atrial natriuretic peptide (la-anp) and methods for use thereof |
EP2475396A4 (en) * | 2009-09-10 | 2013-10-16 | Univ Pittsburgh | ARTIFICIAL MICROPARTICLES FOR THE ADMINISTRATION OF MACROMOLECULES |
NZ598686A (en) * | 2009-09-28 | 2014-05-30 | Intarcia Therapeutics Inc | Rapid establishment and/or termination of substantial steady-state drug delivery |
CN107412749A (zh) * | 2010-02-22 | 2017-12-01 | 优势医疗公司 | 治疗脑的出血性病状的方法和组合物 |
KR101319420B1 (ko) * | 2011-03-18 | 2013-10-17 | 한남대학교 산학협력단 | 서방형 방출이 가능한 수용성 양이온 약물 전달 시스템 |
CN103906761B (zh) | 2011-08-30 | 2016-12-21 | 梅约医学教育与研究基金会 | 利钠多肽 |
US9611305B2 (en) | 2012-01-06 | 2017-04-04 | Mayo Foundation For Medical Education And Research | Treating cardiovascular or renal diseases |
CN102552166A (zh) * | 2012-01-09 | 2012-07-11 | 北京化工大学 | 一种溶菌酶/聚(α-氰基丙烯酸异丁酯)载药微球的制备方法 |
CN102552169B (zh) * | 2012-02-17 | 2015-07-29 | 深圳市健元医药科技有限公司 | 一种醋酸阿肽地尔缓释微球制剂及其制备方法 |
BR112014028600B1 (pt) | 2012-05-18 | 2022-11-22 | Genentech, Inc | Formulações de suspensão compreendendo anticorpo monoclonal de alta concentração, seu método de preparação, seu uso e dispositivo para sua administração subcutânea, e método para produção de um artigo de fabricação |
US9040034B2 (en) | 2013-04-09 | 2015-05-26 | International Business Machines Corporation | Vitamin functionalized gel-forming block copolymers for biomedical applications |
US20160303242A1 (en) | 2013-12-09 | 2016-10-20 | Durect Corporation | Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same |
CN103720663B (zh) * | 2014-01-08 | 2016-04-06 | 昆药集团股份有限公司 | 一种促卵泡激素缓释微球及其制备方法 |
HUE037945T2 (hu) | 2014-07-09 | 2018-09-28 | Pf Medicament | Eljárás mozgási rendellenességek kezelésére befiradollal |
US9925233B2 (en) | 2015-01-30 | 2018-03-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9937223B2 (en) | 2015-01-30 | 2018-04-10 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9750785B2 (en) | 2015-01-30 | 2017-09-05 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9687526B2 (en) | 2015-01-30 | 2017-06-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9744209B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9744239B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
CN107849110B (zh) * | 2015-06-12 | 2021-11-26 | 诺和诺德股份有限公司 | 选择性pyy化合物及其用途 |
CN109937046A (zh) | 2016-09-09 | 2019-06-25 | 艾利西斯股份有限公司 | 脂质体抗癌组合物 |
EP3538131A4 (en) | 2016-11-09 | 2020-07-01 | Mayo Foundation for Medical Education and Research | MANP ANALOG |
DE102016013737A1 (de) * | 2016-11-17 | 2018-05-17 | WindplusSonne GmbH | Hexahydroxycyclohexanhexaphosphorsäureestersalze zur Behandlung von Kalzinose sowie diätische Lebensmittel mit Hexahydroxycyclohexanhexaphosphorsäureestersalzen als Zusatzstoffe |
CA3069159A1 (en) | 2017-07-11 | 2019-01-17 | Sustained Nano Systems Llc | Hypercompressed pharmaceutical formulations |
CN111032054A (zh) | 2017-07-11 | 2020-04-17 | 持续纳米系统有限责任公司 | 超压缩聚合物剂型的辐射灭菌 |
KR102137786B1 (ko) * | 2018-07-19 | 2020-07-24 | 주식회사 아울바이오 | 주사제용 미립구의 제조방법 |
CN113164395A (zh) | 2018-10-15 | 2021-07-23 | 株式会社钟根堂 | 注射用长效纳屈酮微粒组合物 |
US11633416B1 (en) | 2020-03-06 | 2023-04-25 | Arcus Biosciences, Inc. | Oral formulations of CD73 compounds |
CN112661958B (zh) * | 2020-12-09 | 2023-03-17 | 中山大学 | 一种基于肌醇和精氨酸的聚酯酰胺及其制备方法与应用 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4675189A (en) * | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
IE52535B1 (en) * | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US5059591B1 (en) * | 1983-05-26 | 2000-04-25 | Liposome Co Inc | Drug preparations of reduced toxicity |
US4578384A (en) * | 1984-02-15 | 1986-03-25 | The United States Of America As Represented By The Secretary Of The Army | Polylactic-polyglycolic acids combined with an acidic phospholipid-lysozyme complex for healing osseous tissue |
JP2551756B2 (ja) | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
US6312679B1 (en) * | 1986-08-18 | 2001-11-06 | The Dow Chemical Company | Dense star polymer conjugates as dyes |
US4728202A (en) * | 1987-01-14 | 1988-03-01 | Emerson Electric Co. | Shaft locking collar for bearing assemblies |
US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US5538739A (en) * | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
US5077049A (en) * | 1989-07-24 | 1991-12-31 | Vipont Pharmaceutical, Inc. | Biodegradable system for regenerating the periodontium |
US5225205A (en) * | 1989-07-28 | 1993-07-06 | Debiopharm S.A. | Pharmaceutical composition in the form of microparticles |
DE4004430A1 (de) * | 1990-02-09 | 1991-08-14 | Schering Ag | Aus polyaldehyden aufgebaute kontrastmittel |
MY107937A (en) * | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
JPH0426630A (ja) * | 1990-05-19 | 1992-01-29 | Wakiyou Kagaku Kogyo Kk | 水性製剤におけるリゾチーム塩の安定化方法 |
US5410016A (en) * | 1990-10-15 | 1995-04-25 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
US5529914A (en) * | 1990-10-15 | 1996-06-25 | The Board Of Regents The Univeristy Of Texas System | Gels for encapsulation of biological materials |
SE469260B (sv) * | 1992-02-25 | 1993-06-14 | Perstorp Ab | En farmaceutisk komposition med foerbaettrad biotillgaenglighet avseende inositolfosfat |
ATE154240T1 (de) | 1992-03-12 | 1997-06-15 | Alkermes Inc | Acth enthaltende mikrokugeln mit gesteuerter abgabe |
ATE195652T1 (de) * | 1992-12-02 | 2000-09-15 | Alkermes Inc | Wachstumhormon enthaltende mikrosphaeren mit kontrollierter freisetzung |
US5595760A (en) * | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
WO1996021440A1 (en) * | 1995-01-09 | 1996-07-18 | Alpha-Therapeutics, Inc. | Methods for increasing the bioavailability of biological active agents |
US5698213A (en) * | 1995-03-06 | 1997-12-16 | Ethicon, Inc. | Hydrogels of absorbable polyoxaesters |
US6410044B1 (en) * | 1998-03-19 | 2002-06-25 | Surmodics, Inc. | Crosslinkable macromers |
KR19990085365A (ko) * | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
US6461631B1 (en) * | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
WO2002010177A1 (en) * | 2000-08-01 | 2002-02-07 | Gmp Companies, Inc. | Ammonium salts of inositol hexaphosphate and uses thereof |
IL140017A (en) * | 2000-11-30 | 2009-09-22 | Abraham J Domb | Polyhedra |
US6592899B2 (en) * | 2001-10-03 | 2003-07-15 | Macromed Incorporated | PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water |
US7226624B2 (en) * | 2002-07-24 | 2007-06-05 | Rabinowitz Israel N | Synergistic compositions from yeast-modified aqueous extracts from almond hulls |
WO2004017913A2 (en) * | 2002-08-22 | 2004-03-04 | Nutrition 21, Inc. | Arginine silicate inositol complex and use thereof |
WO2004035762A2 (en) * | 2002-10-17 | 2004-04-29 | Alkermes Controlled Therapeutics, Inc. Ii | Microencapsulation and sustained release of biologically active polypeptides |
US20040097419A1 (en) * | 2002-11-19 | 2004-05-20 | Holger Petersen | Organic compounds |
EP1786400B1 (en) * | 2004-08-12 | 2009-03-11 | Quest Pharmaceutical Services | Pharmaceutical compositions for controlled release delivery of biologically active compounds |
-
2005
- 2005-08-11 EP EP05807464A patent/EP1786400B1/en not_active Not-in-force
- 2005-08-11 AU AU2005271242A patent/AU2005271242B9/en not_active Ceased
- 2005-08-11 KR KR1020077005752A patent/KR101231856B1/ko active IP Right Grant
- 2005-08-11 WO PCT/US2005/028676 patent/WO2006017852A2/en active Application Filing
- 2005-08-11 US US11/201,932 patent/US7964219B2/en not_active Expired - Fee Related
- 2005-08-11 AT AT05807464T patent/ATE424848T1/de active
- 2005-08-11 RU RU2007105872/15A patent/RU2390355C2/ru not_active IP Right Cessation
- 2005-08-11 ES ES05807464T patent/ES2323141T3/es active Active
- 2005-08-11 BR BRPI0514297-0A patent/BRPI0514297A/pt not_active IP Right Cessation
- 2005-08-11 CN CN2005800337160A patent/CN101035512B/zh not_active Expired - Fee Related
- 2005-08-11 NZ NZ553149A patent/NZ553149A/en not_active IP Right Cessation
- 2005-08-11 JP JP2007525814A patent/JP5053846B2/ja not_active Expired - Fee Related
- 2005-08-11 DK DK05807464T patent/DK1786400T3/da active
- 2005-08-11 PL PL05807464T patent/PL1786400T3/pl unknown
- 2005-08-11 MX MX2007001760A patent/MX2007001760A/es active IP Right Grant
- 2005-08-11 SI SI200530705T patent/SI1786400T1/sl unknown
- 2005-08-11 PT PT05807464T patent/PT1786400E/pt unknown
- 2005-08-11 DE DE602005013244T patent/DE602005013244D1/de active Active
- 2005-08-11 CA CA2576689A patent/CA2576689C/en not_active Expired - Fee Related
-
2008
- 2008-03-06 HK HK08102665.2A patent/HK1108638A1/xx not_active IP Right Cessation
-
2009
- 2009-06-11 CY CY20091100618T patent/CY1109425T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU2005271242A1 (en) | 2006-02-16 |
DK1786400T3 (da) | 2009-06-29 |
AU2005271242B2 (en) | 2011-09-15 |
CN101035512A (zh) | 2007-09-12 |
NZ553149A (en) | 2010-01-29 |
PT1786400E (pt) | 2009-06-19 |
BRPI0514297A (pt) | 2008-06-10 |
CN101035512B (zh) | 2012-01-18 |
WO2006017852A3 (en) | 2006-08-31 |
CA2576689C (en) | 2012-10-09 |
PL1786400T3 (pl) | 2009-08-31 |
WO2006017852A2 (en) | 2006-02-16 |
SI1786400T1 (sl) | 2009-08-31 |
KR101231856B1 (ko) | 2013-02-08 |
US20060034923A1 (en) | 2006-02-16 |
MX2007001760A (es) | 2007-07-24 |
US7964219B2 (en) | 2011-06-21 |
ATE424848T1 (de) | 2009-03-15 |
EP1786400A4 (en) | 2008-07-09 |
JP2008511544A (ja) | 2008-04-17 |
DE602005013244D1 (de) | 2009-04-23 |
RU2390355C2 (ru) | 2010-05-27 |
HK1108638A1 (en) | 2008-05-16 |
EP1786400B1 (en) | 2009-03-11 |
RU2007105872A (ru) | 2008-09-20 |
JP5053846B2 (ja) | 2012-10-24 |
CA2576689A1 (en) | 2006-02-16 |
AU2005271242A2 (en) | 2006-02-16 |
ES2323141T3 (es) | 2009-07-07 |
EP1786400A2 (en) | 2007-05-23 |
AU2005271242B9 (en) | 2012-04-12 |
KR20070043881A (ko) | 2007-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1109425T1 (el) | Φαρμακευτικες συνθεσεις για τη χορηγηση με ελεγχομενη αποδεσμευση βιολογικα δραστικων ενωσεων | |
EA200800161A1 (ru) | Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций | |
ES2762460T3 (es) | Composiciones y métodos de administración dérmica | |
WO2007084460A3 (en) | Pharmaceutical compositions with enhanced stability | |
TW200503775A (en) | Pharmaceutical composition and method for treating | |
BR112013016772B8 (pt) | compostos, uso do composto e composição farmacêutica | |
NZ610315A (en) | Antiviral condensed heterocyclic compounds | |
MX2009000812A (es) | Soluciones de metotrexato concentradas. | |
GEP20125628B (en) | Pharmaceutical compositions containing antagonist anti-cd40 antibody | |
GEP20115200B (en) | Stable pharmaceutical composition containing docetaxel and a method of manufacturing the same | |
WO2013036309A3 (en) | Sustained release formulations for delivery of proteins to the eye and methods of preparing same | |
PE20060244A1 (es) | Formulacion farmaceutica de deposito que contiene polietilenglicol de peso molecular menor a 600 daltones | |
WO2010103544A3 (en) | A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants | |
UA110013C2 (uk) | Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів | |
EP3146980A1 (en) | Rotigotine-containing transdermal absorption preparation with improved stability | |
EA200971132A1 (ru) | Фармацевтическая композиция с пролонгированным высвобождением, приготовленная из микрочастиц | |
WO2009145594A3 (ko) | 약물전달체 | |
UA93365C2 (ru) | Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты) | |
Dong et al. | Inhibition of Toll-like receptor-mediated inflammation in vitro and in vivo by a novel benzoxaborole | |
PE20130782A1 (es) | Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo | |
TW200740440A (en) | Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient | |
WO2008033058A3 (fr) | Procédé permettant de produire une préparation d'insuline pour administration orale | |
MX2021002385A (es) | Composicion farmaceutica para administracion oral. | |
EA200701525A1 (ru) | Фармацевтическая полимерная композиция для перорального введения тербуталина сульфата с контролируемым высвобождением | |
MXPA06000760A (es) | Composicion farmaceutica estable de carisoprodol y meloxicam. |